Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study

BMC Infectious Diseases

Research Article

Jean-Didier Cavallo¹  Jeanne Maugein²  Claudette Muller-Serieys³  Micheline Roussel-Delvallez⁴  Monique Chomarat⁵  Marie-Laure Joly-Guillou⁶  Marie Kempf⁶  Luc Dubreuil⁷ 

[1] Bacteriology department, Begin Military Hospital, Paris Ave, 94163, St Mandé, France;Bacteriology department, Haut Leveque Hospital, Magellan Ave, 33604, Pessac, France;Bacteriology department, Universitary Hospital Bichat Claude Bernard, AP-HP, 75018, Paris, France;Bacteriology department, Universitary Hospital Calmette, J. Leclercq Bd, 59037, Lille, France;Bacteriology department, Universitary Hospital Lyon-Sud, 69310, Pierre Bénite, France;Bacteriology department, Universitary Hospital, Larrey St, 49000, Angers, France;Faculty of Pharmacy, Dr Laguesse St, 59006, Lille, France;

关键词: Imipenem;    Meropenem;    Carbapenems;    AmpC;    Susceptible Strain;   

DOI  :  10.1186/1471-2334-10-72

 received in 2009-03-11, accepted in 2010-03-18,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundMeropenem is a carbapenem that has an excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria. The major objective of the present study was to assess the in vitro activity of meropenem compared to imipenem and piperacillin/tazobactam, against 1071 non-repetitive isolates collected from patients with bacteremia (55%), pneumonia (29%), peritonitis (12%) and wound infections (3%), in 15 French hospitals in 2006. The secondary aim of the study was to compare the results of routinely testings and those obtained by a referent laboratory.MethodSusceptibility testing and Minimum Inhibitory Concentrations (MICs) of meropenem, imipenem and piperacillin/tazobactam were determined locally by Etest method. Susceptibility to meropenem was confirmed at a central laboratory by disc diffusion method and MICs determined by agar dilution method for meropenem, imipenem and piperacillin/tazobactam.ResultsCumulative susceptibility rates against Escherichia coli were, meropenem and imipenem: 100% and piperacillin/tazobactam: 90%. Against other Enterobacteriaceae, the rates were meropenem: 99%, imipenem: 98% and piperacillin/tazobactam: 90%. All Staphylococci, Streptococci and anaerobes were susceptible to the three antibiotics. Against non fermeters, meropenem was active on 84-94% of the strains, imipenem on 84-98% of the strains and piperacillin/tazobactam on 90-100% of the strains.ConclusionsCompared to imipenem, meropenem displays lower MICs against Enterobacteriaceae, Escherichia coli and Pseudomonas aeruginosa. Except for non fermenters, MICs90 of carbapenems were <4 mg/L. Piperacillin/tazobactam was less active against Enterobacteriaceae and Acinetobacter but not P. aeruginosa. Some discrepancies were noted between MICs determined by Etest accross centres and MICs determined by agar dilution method at the central laboratory. Discrepancies were more common for imipenem testing and more frequently related to a few centres. Overall MICs determined by Etest were in general higher (0.5 log to 1 log fold) than MICs by agar dilution.

【 授权许可】

CC BY   
© Joly-Guillou et al; licensee BioMed Central Ltd. 2010